Chemical
Rossari Biotech's income doubles in Q4FY22
Net profit rose by 7.38% to reach Rs.24.08 crores in Q4FY22 versus Rs.22.42 crores for the period ended March 31, 2021
-
By ICN Bureau | May 20, 2022
Rossari Biotech Limited has reported consolidated financial results for the period ended March 31, 2022. The company's total income jumped by 100% to reach Rs. 440.90 crores in Q4FY22 as against Rs.220.26 crores in the same quarter last year.
Net profit rose by 7.38% to reach Rs.24.08 crores in Q4FY22 versus Rs.22.42 crores for the period ended March 31, 2021.
The company has reported EPS growth of 1.40% at Rs. 4.35 in Q4 as compared to Rs.4.29 for the period ended March 31, 2021.
The company's board has recommended final dividend of 25% (i.e. Re. 0.50 /- per share) on equity shares of the face value of Rs. 2/- each for FY22, subject to approval of the shareholders at the forthcoming AGM.
For the full year, the company's total income grew by 108% to reach Rs.1494.97 crores in FY22 as compared to Rs.718.04 crores in FY21.
Company's net profit rose by 21.76% and stood at Rs.97.674 crores in FY22 as against Rs.80.22 crores in FY21.
The company has reported EPS of Rs.17.70 in FY22 as compared to Rs.15.47 last year.
